Edastar 1.5 mg Injection

Edaravone belongs to a class of medications known as free radical scavengers, which work by neutralizing harmful molecules called free radicals that can cause oxidative damage to nerve cells and surrounding tissue. In ALS, a progressive condition affecting nerve cells that control voluntary muscle movement, Edaravone helps protect remaining healthy nerve cells from further oxidative damage, which may help slow the decline in physical function for some patients. It is also used in certain countries to support recovery following an acute ischemic stroke, where reducing oxidative stress in the affected brain tissue may help limit the extent of damage during the critical recovery period. For ALS treatment, Edaravone is typically administered through intravenous infusion or, in some formulations, as an oral suspension, following a specific treatment cycle that includes an initial daily dosing period followed by scheduled treatment cycles with rest periods in between. Treatment is generally started and monitored by a neurologist experienced in managing ALS, with regular follow-up to assess response and overall health. For stroke-related use, it is typically administered as soon as possible after the stroke occurs, as part of acute hospital care under close medical supervision. Many patients with ALS who use Edaravone as part of their treatment plan experience some slowing in the progression of physical decline, though individual responses can vary. As with all specialized neurological treatments, Edaravone should be used under the close guidance of a healthcare provider experienced in treating the specific condition.